Intratumoral Tcf1 + PD-1 + CD8 + T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

Immunity

Volumn 50, Issue 1, 2019, Pages 195-211.e10

  Siddiqui, Imran ^a   Schaeuble, Karin ^a   Chennupati, Vijaykumar ^a   Fuertes Marraco, Silvia A ^a   Calderon Copete, Sandra ^b   Pais Ferreira, Daniela ^a   Carmona, Santiago J ^a,b,c   Scarpellino, Leonardo ^b   Gfeller, David ^a,b,c   Pradervand, Sylvain ^b   Luther, Sanjiv A ^b   Speiser, Daniel E ^a   Held, Werner ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

cancer immunotherapy; checkpoint blockade; memory like T cells; stem like T cells; T cell exhaustion; T cell factor 1; T cell reinvigoration; therapeutic vaccination

Indexed keywords

CD244 PROTEIN; CD3 ANTIGEN; CD8ALPHA ANTIGEN; CHECKPOINT KINASE INHIBITOR; CHEMOKINE RECEPTOR CCR7; DIPHTHERIA TOXIN; FINGOLIMOD; GILVETMAB; GLYCOPROTEIN GP 100; GP33 PEPTIDE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INHIBITOR OF DIFFERENTIATION 3; IPILIMUMAB; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELAN A; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; PROTEIN BCL 6; TETRAMER; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR MAF; TRANSCRIPTOME; TRP2 ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL SELF-RENEWAL; CELL TRANSFER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MELANOMA CELL LINE; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA SEQUENCE; STEM CELL; TERTIARY LYMPHOID STRUCTURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VACCINATION; VIRUS INFECTION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; STEM CELLS; T-LYMPHOCYTE SUBSETS;

EID: 85059786958     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2018.12.021     Document Type: Article

References (56)

1. Anders, S., Pyl, P.T., Huber, W., HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31 (2015), 166–169.
2. + T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
3. Broz, M.L., Binnewies, M., Boldajipour, B., Nelson, A.E., Pollack, J.L., Erle, D.J., Barczak, A., Rosenblum, M.D., Daud, A., Barber, D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26 (2014), 638–652.
4. + T cells infiltrating human tumors. J. Exp. Med. 215 (2018), 2520–2535.
5. Chen, D.S., Mellman, I., Elements of cancer immunity and the cancer-immune set point. Nature 541 (2017), 321–330.
6. Danilo, M., Chennupati, V., Silva, J.G., Siegert, S., Held, W., Suppression of Tcf1 by inflammatory cytokines facilitates effector CD8 T cell differentiation. Cell Rep. 22 (2018), 2107–2117.
7. Dillon, S.R., Jameson, S.C., Fink, P.J., V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition. J. Immunol. 152 (1994), 1790–1801.
8. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
9. Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
10. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124 (2014), 2246–2259.
11. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.-J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
12. Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bevan, M.J., Carbone, F.R., T cell receptor antagonist peptides induce positive selection. Cell 76 (1994), 17–27.
13. + T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer Immunol. Res. 6 (2018), 14–24.
14. Huang, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
15. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
16. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., Speed, T.P., Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003), 249–264.
17. Ivanova, N.B., Dimos, J.T., Schaniel, C., Hackney, J.A., Moore, K.A., Lemischka, I.R., A stem cell molecular signature. Science 298 (2002), 601–604.
18. Jeannet, G., Boudousquié C., Gardiol, N., Kang, J., Huelsken, J., Held, W., Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc. Natl. Acad. Sci. USA 107 (2010), 9777–9782.
19. Joshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., Kaech, S.M., Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27 (2007), 281–295.
20. Kamphorst, A.O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D.L., Konieczny, B.T., Daugherty, C.Z., Koenig, L., Yu, K., et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355 (2017), 1423–1427.
21. Law, C.W., Chen, Y., Shi, W., Smyth, G.K., voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol., 15, 2014, R29.
22. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
23. Mackay, L.K., Rahimpour, A., Ma, J.Z., Collins, N., Stock, A.T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S.N., Stefanovic, T., et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat. Immunol. 14 (2013), 1294–1301.
24. Mackay, L.K., Minnich, M., Kragten, N.A.M., Liao, Y., Nota, B., Seillet, C., Zaid, A., Man, K., Preston, S., Freestone, D., et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science 352 (2016), 459–463.
25. Majewski, I.J., Ritchie, M.E., Phipson, B., Corbin, J., Pakusch, M., Ebert, A., Busslinger, M., Koseki, H., Hu, Y., Smyth, G.K., et al. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood 116 (2010), 731–739.
26. Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002), 346–349.
27. Martin, M.T., Knudsen, T.B., Reif, D.M., Houck, K.A., Judson, R.S., Kavlock, R.J., Dix, D.J., Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol. Reprod. 85 (2011), 327–339.
28. Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D., Immune modulation in cancer with antibodies. Annu. Rev. Med. 65 (2014), 185–202.
29. Prévost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F.M., Pircher, H., Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161 (1998), 2187–2194.
30. Reiser, J., Banerjee, A., Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J. Immunol. Res., 2016, 2016, 8941260.
31. Ribas, A., Wolchok, J.D., Cancer immunotherapy using checkpoint blockade. Science 359 (2018), 1350–1355.
32. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
33. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
34. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
35. Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, J.H., Frederick, D.T., Barzily-Rokni, M., et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175 (2018), 998–1013.e20.
36. Schaeuble, K., Britschgi, M.R., Scarpellino, L., Favre, S., Xu, Y., Koroleva, E., Lissandrin, T.K.A., Link, A., Matloubian, M., Ware, C.F., et al. Perivascular fibroblasts of the developing spleen act as LTα1β2-dependent precursors of both T and B zone organizer cells. Cell Rep. 21 (2017), 2500–2514.
37. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
38. + T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557 (2018), 575–579.
39. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166 (2016), 1500–1511.e9.
40. Speiser, D.E., Utzschneider, D.T., Oberle, S.G., Münz, C., Romero, P., Zehn, D., T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. Nat. Rev. Immunol. 14 (2014), 768–774.
41. Spranger, S., Koblish, H.K., Horton, B., Scherle, P.A., Newton, R., Gajewski, T.F., Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer, 2, 2014, 3.
42. + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24 (2018), 994–1004.
43. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
44. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
45. Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45 (2016), 415–427.
46. Verbeek, S., Izon, D., Hofhuis, F., Robanus-Maandag, E., te Riele, H., van de Wetering, M., Oosterwegel, M., Wilson, A., MacDonald, H.R., Clevers, H., An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature 374 (1995), 70–74.
47. Wang, L., Wang, S., Li, W., RSeQC: quality control of RNA-seq experiments. Bioinformatics 28 (2012), 2184–2185.
48. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.e17.
49. Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
50. Wong, D.J., Liu, H., Ridky, T.W., Cassarino, D., Segal, E., Chang, H.Y., Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2 (2008), 333–344.
51. Wu, D., Smyth, G.K., Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res., 40, 2012, e133.
52. Wu, T., Shin, H.M., Moseman, E.A., Ji, Y., Huang, B., Harly, C., Sen, J.M., Berg, L.J., Gattinoni, L., McGavern, D.B., Schwartzberg, P.L., TCF1 is required for the T follicular helper cell response to viral infection. Cell Rep. 12 (2015), 2099–2110.
53. Wu, T., Ji, Y., Moseman, E.A., Xu, H.C., Manglani, M., Kirby, M., Anderson, S.M., Handon, R., Kenyon, E., Elkahloun, A., et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol., 1, 2016, 1.
54. Xing, S., Li, F., Zeng, Z., Zhao, Y., Yu, S., Shan, Q., Li, Y., Phillips, F.C., Maina, P.K., Qi, H.H., et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat. Immunol. 17 (2016), 695–703.
55. Yu, G., Wang, L.G., He, Q.Y., ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31 (2015), 2382–2383.
56. Zhou, X., Yu, S., Zhao, D.M., Harty, J.T., Badovinac, V.P., Xue, H.H., Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 33 (2010), 229–240.